Ocuphire Pharma Inc.

11/23/2021 | Press release | Distributed by Public on 11/23/2021 08:02

Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)